AR046131A1 - Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona - Google Patents

Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona

Info

Publication number
AR046131A1
AR046131A1 ARP040103801A ARP040103801A AR046131A1 AR 046131 A1 AR046131 A1 AR 046131A1 AR P040103801 A ARP040103801 A AR P040103801A AR P040103801 A ARP040103801 A AR P040103801A AR 046131 A1 AR046131 A1 AR 046131A1
Authority
AR
Argentina
Prior art keywords
piridin
triazol
chlorophenyl
bistrifluorurometilbencil
metanone
Prior art date
Application number
ARP040103801A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR046131A1 publication Critical patent/AR046131A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP040103801A 2003-10-24 2004-10-20 Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona AR046131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
AR046131A1 true AR046131A1 (es) 2005-11-23

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103801A AR046131A1 (es) 2003-10-24 2004-10-20 Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona

Country Status (28)

Country Link
US (1) US7381826B2 (https=)
JP (1) JP4959336B2 (https=)
KR (1) KR100848407B1 (https=)
CN (1) CN1863791B (https=)
AR (1) AR046131A1 (https=)
AT (1) ATE462700T1 (https=)
AU (1) AU2004285855B8 (https=)
BR (1) BRPI0415010B8 (https=)
CA (1) CA2542140C (https=)
CL (2) CL2009001310A1 (https=)
CR (1) CR8353A (https=)
DE (1) DE602004026333D1 (https=)
DK (1) DK1675846T3 (https=)
EA (1) EA008881B1 (https=)
EC (1) ECSP066517A (https=)
ES (1) ES2340772T3 (https=)
HR (1) HRP20100207T1 (https=)
IL (1) IL174926A0 (https=)
MA (1) MA28329A1 (https=)
MY (1) MY157375A (https=)
NO (1) NO335090B1 (https=)
NZ (2) NZ580480A (https=)
PE (1) PE20050481A1 (https=)
PT (1) PT1675846E (https=)
TW (1) TW200524906A (https=)
UA (1) UA82901C2 (https=)
WO (1) WO2005042515A1 (https=)
ZA (1) ZA200603234B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}·(2-氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Also Published As

Publication number Publication date
MY157375A (en) 2016-06-15
HRP20100207T1 (hr) 2010-05-31
AU2004285855B8 (en) 2011-04-28
UA82901C2 (en) 2008-05-26
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
CA2542140C (en) 2012-05-29
NO335090B1 (no) 2014-09-08
CN1863791A (zh) 2006-11-15
PT1675846E (pt) 2010-04-20
ES2340772T3 (es) 2010-06-09
JP4959336B2 (ja) 2012-06-20
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B2 (en) 2010-12-23
CL2009001310A1 (es) 2009-12-04
BRPI0415010B8 (pt) 2021-05-25
DK1675846T3 (da) 2010-05-31
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12
BRPI0415010A8 (pt) 2018-05-08
CA2542140A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
ZA200603234B (en) 2007-07-25
KR20060061388A (ko) 2006-06-07
ATE462700T1 (de) 2010-04-15
PE20050481A1 (es) 2005-09-20
US20070078166A1 (en) 2007-04-05
WO2005042515A1 (en) 2005-05-12
MA28329A1 (fr) 2006-12-01
IL174926A0 (en) 2006-08-20
CL2009001311A1 (es) 2009-10-02
NZ545917A (en) 2009-11-27
CR8353A (es) 2006-06-06
TW200524906A (en) 2005-08-01
KR100848407B1 (ko) 2008-07-28
BRPI0415010B1 (pt) 2019-07-09
CN1863791B (zh) 2011-12-07
EA008881B1 (ru) 2007-08-31
ECSP066517A (es) 2006-10-10
AU2004285855A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
CR8291A (es) Formas polimorficas 3-(4-amino-1-oxo-1,3 dihidro -isoindol-2-il)-piperidin-2, 6-diona
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CY1109072T1 (el) Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν
NO20055135L (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
NO20053647L (no) Pyrazolopyridinderivater
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
DOP2003000561A (es) 2-(piridin-2-ilamino)-pirido [2, 3-d] pirimindin-7-onas
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR9505A (es) Formas cristalinas anhidras de la n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-cabonil)metanosulfonamida
CR10156A (es) Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20071100L (no) 5-jodtetrazoler
DK1660485T3 (da) Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
DOP2004001016A (es) Nuevas formas critalinas de {2-[1-(3,5-bistrifluorometibencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-2(-clorofenil) metanona.
EE200300365A (et) Parendatud toimega tsüklilise depsipeptiidi kristallivorm
ITMI20030018A1 (it) Procedimento per la preparazione di composti mono-

Legal Events

Date Code Title Description
FA Abandonment or withdrawal